Durvalumab, a PD-L1 suppressor, gained recent FDA approval as a consolidation drug following CCRT; this medication represents a major progress in the treatment of unresectable stage III NSCLC [22]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.